DENTSPLY SIRONA Inc (NASDAQ:XRAY) has earned an average recommendation of “Hold” from the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $56.77.

XRAY has been the subject of several research reports. Zacks Investment Research upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research note on Tuesday. JPMorgan Chase & Co. lowered DENTSPLY SIRONA from an “overweight” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Wednesday. They noted that the move was a valuation call. BidaskClub lowered DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright reiterated a “hold” rating and set a $60.00 price objective on shares of DENTSPLY SIRONA in a research note on Friday, November 15th. Finally, ValuEngine lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd.

NASDAQ:XRAY opened at $56.38 on Wednesday. DENTSPLY SIRONA has a 12 month low of $34.93 and a 12 month high of $60.15. The stock has a 50 day moving average of $56.35 and a two-hundred day moving average of $54.84. The company has a current ratio of 2.08, a quick ratio of 1.39 and a debt-to-equity ratio of 0.30. The firm has a market cap of $12.54 billion, a P/E ratio of 28.05, a price-to-earnings-growth ratio of 1.99 and a beta of 0.95.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.57 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.07. DENTSPLY SIRONA had a return on equity of 10.08% and a net margin of 4.08%. The company had revenue of $962.10 million during the quarter, compared to analyst estimates of $940.38 million. During the same period in the previous year, the business earned $0.38 EPS. DENTSPLY SIRONA’s quarterly revenue was up 3.6% on a year-over-year basis. On average, research analysts forecast that DENTSPLY SIRONA will post 2.45 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Stockholders of record on Friday, December 27th will be given a $0.10 dividend. The ex-dividend date of this dividend is Thursday, December 26th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 0.71%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently 19.90%.

In other news, Director Michael C. Alfano sold 10,665 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $56.27, for a total value of $600,119.55. Following the completion of the sale, the director now directly owns 15,153 shares in the company, valued at $852,659.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.62% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of XRAY. Vanguard Group Inc. grew its position in shares of DENTSPLY SIRONA by 7.0% in the second quarter. Vanguard Group Inc. now owns 25,969,056 shares of the medical instruments supplier’s stock valued at $1,515,556,000 after purchasing an additional 1,688,546 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of DENTSPLY SIRONA by 286.7% in the third quarter. Point72 Asset Management L.P. now owns 1,501,763 shares of the medical instruments supplier’s stock valued at $80,059,000 after purchasing an additional 1,113,453 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of DENTSPLY SIRONA in the second quarter valued at approximately $64,278,000. Eagle Asset Management Inc. grew its position in shares of DENTSPLY SIRONA by 2,650.9% in the second quarter. Eagle Asset Management Inc. now owns 952,733 shares of the medical instruments supplier’s stock valued at $55,601,000 after purchasing an additional 918,100 shares in the last quarter. Finally, Parnassus Investments CA grew its position in shares of DENTSPLY SIRONA by 54.8% in the third quarter. Parnassus Investments CA now owns 2,403,989 shares of the medical instruments supplier’s stock valued at $128,157,000 after purchasing an additional 850,850 shares in the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Further Reading: Reverse Stock Split

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.